# EDGAR Filing Document

**Accession Number:** 0001932843
**File Stem:** 0000921895-25-002135
**Filing Date:** 2025-8
**Character Count:** 5278
**Document Hash:** 07442e0e0ce87dcc31119550df13151c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002135.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0000921895-25-002135

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-80136
- **FILM NUMBER:** 251196741

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lazar David E.
- **CENTRAL INDEX KEY:** 0001932843

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 44, TOWER 100, THE TOWERS
- **STREET 2:** WINSTON CHURCHILL, PAITILLA
- **CITY:** PANAMA CITY
- **STATE:** R1
- **ZIP:** 07196

## Ex-1

Exhibit 1

**<u>Transactions in the Securities of the Issuer During the Past Sixty Days</u>**

---

| | | |
|:---|:---|:---|
| <u>Shares of Common Stock Sold</u> | <u>Price Per Share</u> | <u>Date of Sale</u> |
| 15011 | $9.65 | 8/4/2025 |
| 114618 | $9.31 | 8/5/2025 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Cyclacel Pharmaceuticals, Inc.**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**23254L801**

*(CUSIP Number)*

**DAVID E. LAZAR**<br>44, Tower 100, The Towers<br>Winston Churchill<br>Panama City R1 07196<br>646-768-8417

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/05/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **23254L801** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Lazar David E.** | Name of reporting person<br>**Lazar David E.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
Cyclacel Pharmaceuticals, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922

The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. As a result of the transactions described herein, the filing of this Amendment No. 2 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Lazar David E.

**Signature:** /s/ David E. Lazar

**Name/Title:** David E. Lazar

**Date:** 08/08/2025